Headache News and Research

Latest Headache News and Research

European Commission and US FDA approve intravenous formulation of temozolomide

Schering-Plough Corporation (NYSE:SGP) today announced that the European Commission and the US FDA both approved the intravenous (IV) formulation of temozolomide as an alternative to the already approved oral form of the drug.

5 Mar 2009

Universal vaccination associated with decreased Canadian cases of most deadly strain of meningitis

Universal childhood vaccination against meningococcal C appears to reduce Canadian incidence of the most deadly strain of bacterial meningitis, reports new research published in the March issue of The Pediatric Infectious Disease Journal.

2 Mar 2009

Experimental animal vaccine may protect humans from Ebola

Protection against Ebola, one of the world's deadliest viruses, can be achieved by a vaccine produced in insect cells, raising prospects for developing an effective vaccine for humans, say scientists at the Southwest Foundation for Biomedical Research (SFBR) in San Antonio.

26 Feb 2009

Scientists identify protein key to Lyme disease

Researchers at UT Southwestern Medical Center have identified a protein that may help give Lyme disease its bite.

9 Feb 2009

World experts meet in Australia to find ways to wipe out malaria

Australia is host to a meeting of World health experts which aims to find ways of eradicating malaria, one of the world's most dangerous killer diseases.

9 Feb 2009

Vitamin B and folic acid - a new and safe treatment for migraine

A new Australian study has revealed that the occurrence and intensity of migraine may be lessened by taking vitamin B and folic acid.

9 Feb 2009

Idenix Pharmaceuticals and GSK sign agreement for novel NNRTI for treatment of HIV

Idenix Pharmaceuticals, Inc. and GlaxoSmithKline (GSK) today announced the execution of a license agreement granting GSK exclusive worldwide rights to IDX899.

8 Feb 2009

Good news for folks is bad news for mozzies!

Australian scientists have good news for folks but bad news for 'mozzies' with the discovery a possible new treatment for malaria.

8 Feb 2009

FDA grants priority review of Cinryze C1 inhibitor as treatment for acute attacks of hereditary angioedema

ViroPharma Incorporated has announced that the U.S. Food and Drug Administration (FDA) has granted priority review for Cinryze C1 Inhibitor (human) as a treatment for acute attacks of Hereditary Angioedema (HAE).

5 Feb 2009

Discovery introduces a lot of new questions about nervous system

A delay in traffic may cause a headache, but a delay in the nervous system can cause much more.

3 Feb 2009

Economic burden of migraine in the U.S.

A new study published in Value in Health reviews the economic burden of migraine in the U.S. and recent clinical findings of the health risks of this neurological condition.

2 Feb 2009

Healthcare will be a headache for Obama

Among industrialised nations, the US spends well over twice the per capita average on health care and soaring health costs are expected to reach 20 per cent of Gross Domestic Product by 2015.

23 Jan 2009

Migraines linked to mental disorders

Migraine headaches can precede the onset of mental disorders, according to a growing body of knowledge that includes a new study in the January-February 2009 issue of General Hospital Psychiatry.

21 Jan 2009

FDA approves RiaSTAP for bleeding in patients with congenital fibrinogen deficiency

The U.S. Food and Drug Administration has licensed RiaSTAP, an orphan drug for the treatment of bleeding in patients with a rare genetic defect known as congenital fibrinogen deficiency. Without treatment, these patients are at risk of potentially life-threatening bleeding.

18 Jan 2009

Phase 3 trial begins for Gammagard liquid plus rHuPH20 in primary immunodeficiency patients

Baxter International Inc. and Halozyme Therapeutics, Inc. gas announced the start of a Phase 3 clinical trial of Baxter's Gammagard Liquid [Immune Globulin Intravenous] 10% (IGIV), marketed as KIOVIG in the European Union, with Halozyme's recombinant human hyaluronidase enzyme (rHuPH20, Enhanze Technology) for the treatment of primary immunodeficiency (PID).

From Baxter International Inc. 5 Jan 2009